The Peptide Field. Afamelanotide: approval and evidence record.

Editorial review: 2026-07-23. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/afamelanotide

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=afamelanotide#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: An FDA-approved implant exists for a rare-disease indication

Exact product limits: Scenesse is not the same as every tanning peptide or injection. Scenesse is a healthcare-professional-administered implant. It is not equivalent to tanning peptides, compounded injections, or other melanocortin analogues.

Human outcomes: Strong. Randomized trials support pain-free light-exposure and quality-of-life outcomes in adults with EPP.

Body effects in people: Strong. The approved implant's pharmacology and melanocortin-1 activity are characterized.

What the evidence shows: Randomized trials in erythropoietic protoporphyria, or EPP, reported more pain-free light exposure and improvements in disease-specific quality of life. FDA approved Scenesse for a corresponding adult population.

What remains unknown: The approval does not establish general tanning, cosmetic anti-aging, athletic, or other disease benefits. It does not validate different melanocortin peptides.

Safety limits: The implant is administered by trained healthcare professionals and the label calls for skin monitoring. This guide provides no implant or cosmetic-use instructions.

Product record: Scenesse. Form: Controlled-release implant. Route: Subcutaneous implant administered by a trained professional.
Scope: Increase pain-free light exposure in adults with erythropoietic protoporphyria and a history of phototoxic reactions.
Published label: 2024 label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf

Approval claim: “Scenesse is an approved cosmetic tanning implant.”
Verdict: Misleading. Its approval is for pain-free light exposure in adults with EPP, not cosmetic tanning.
Evidence basis: Regulatory or product record. Scope: The current FDA-approved indication.
Claim sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. SCENESSE (afamelanotide) prescribing information. 2024. Accessed 2026-07-23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf

PubMed · New England Journal of Medicine. Afamelanotide for erythropoietic protoporphyria. 2015. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/26132941/

U.S. Food and Drug Administration. Afamelanotide orphan drug designation and approval. 2019. Accessed 2026-07-23. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208

Keep the limits, review date, and sources with this record. Check the current source for changes.